Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, Boonsathorn S, Chantasrisawad N, Sudjaritruk T, Niyomnaitham S, Senawong S, Srisutthisamphan K, Quan Toh Z, Rungmaitree S, Nanthapisal S, Phanthanawiboon S, Khantee P, Techasaensiri C, Hirankarn N, Pangprasertkul S, Chokephaibulkit K.
Wittawatmongkol O, et al. Among authors: chantasrisawad n.
Vaccine. 2023 Sep 15;41(40):5834-5840. doi: 10.1016/j.vaccine.2023.08.021. Epub 2023 Aug 14.
Vaccine. 2023.
PMID: 37586956
Free article.
Clinical Trial.